Turning RNA Research into Medicines

3:00 PM - 4:00 PM (EST), Wednesday, February 17, 2021
RNA research has long claimed to be a disruptive treatment opportunity, utilizing carefully designed molecules to prompt the body to make its own medicine. With early demonstrations of success in COVID-19 vaccines development touting 90%+ efficacy, there is new excitement in this space, attracting new investments and partnerships. However, the RNA ride has been a rocky one with wins and losses, with some companies investing up to $100m per year in research. Hear from drug developers and scientists as they share their stories and what's to come to realize the long-term vision.
Moderators
photo
analyst
Canaccord Genuity
photo
Managing Director
Canaccord Genuity
Speakers
photo
CTO
HDT Bio
photo
analyst
Canaccord Genuity
photo
Managing Director
Canaccord Genuity
photo
CEO
ReCode Therapeutics, Inc.
photo
CEO
PYC Therapeutics
photo
President and CEO
Shape Therapeutics, Inc.